and 2022 respectively: Foreign Currency Translation; $(
1.1
) billion, $
797
million and $(
460
) million; Employee Benefit Plans: $
86
million, $(
289
) million and $
461
million, Derivatives & Hedges: $(
365
) million, $(
39
) million and $
30
million.
See Notes to Consolidated Financial Statements
Amounts presented for 2023 and 2022 have not been recast to exclude discontinued operations
Johnson & Johnson and subsidiaries consolidated statements of equity
(Dollars in Millions) (Note 1)
See Notes to Consolidated Financial Statements
Johnson & Johnson and subsidiaries consolidated statements of cash flows
(Dollars in Millions) (Note 1)
See Notes to Consolidated Financial Statements
Amounts presented for 2023 and 2022 have not been recast to exclude discontinued operations.
Notes to consolidated financial statements
1.
Summary of significant accounting policies
Principles of consolidation
The consolidated financial statements include the accounts of Johnson & Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.
Description of the company
The Company has approximately
138,100
employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.
Kenvue IPO/separation and discontinued operations
On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of
198,734,444
shares of its common stock, par value $
0.01
per share (the “Kenvue Common Stock”), at an initial public offering of $
22.00
per share for net proceeds of $
4.2
billion. The excess of the net proceeds from the IPO over the net book value of the Johnson & Johnson divested interest was $
2.5
billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson & Johnson owned approximately
89.6
% of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the
non-controlling interest of $
1.3
billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet in the fiscal second quarter of 2023.
On August 23, 2023, Johnson & Johnson completed the disposition of an additional
80.1
% ownership of the shares of Kenvue through an exchange offer. Following the exchange offer, the Company owned
9.5
% of the shares of Kenvue which were accounted for as an equity investment carried at fair value within continuing operations. The historical results of the Consumer Health business (which previously represented the Consumer Health business segment) are reflected as discontinued operations in the Company’s Consolidated Financial Statements through the date of the exchange offer